Moneycontrol
Get App
SENSEX NIFTY
you are here:

Lasa Supergenerics Ltd.

BSE: 540702 | NSE: LASA |

Shares falling in the `Trade-to-Trade` or `T-segment` are traded in this series and no intraday is allowed. This means trades can only be settled by accepting or giving the delivery of shares.
Series: BE | ISIN: INE670X01014 | SECTOR: Miscellaneous

BSE Live

Apr 09, 16:00
34.95 1.65 (4.96%)
Volume
AVERAGE VOLUME
5-Day
33,283
10-Day
19,836
30-Day
23,708
40,681
  • Prev. Close

    33.30

  • Open Price

    34.95

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Apr 09, 15:40
34.05 1.60 (4.93%)
Volume
AVERAGE VOLUME
5-Day
21,664
10-Day
33,488
30-Day
68,288
15,393
  • Prev. Close

    32.45

  • Open Price

    34.05

  • Bid Price (Qty.)

    34.05 (35)

  • Offer Price (Qty.)

    0.00 (0)

Annual Report

For Year :
2018

Chairman's Speech

Dear Fellow Shareholders,

It gives me great pleasure to share with you the highlights of our Company''s performance for the financial year ended March 31,2018.

Our Company has continued to live up to the dedication and commitment towards servicing the veterinary API market. The Company is confident to grow, with growth driven economy across the globe, customer strengthening and huge opportunity lying within Veterinary.

Our ability to offer a wide range of product portfolio and the right product mix through our in-house expertise of catalyst chemistry has made the Company a preferred choice with many clients. Our teams have been constantly engaging in developing new molecules at our R&D facility.

At Lasa Supergenerics, creating value for all stakeholders, including our shareholders has been a defining element of our identity.

Since the demerger of Lasa Supergenerics Ltd., the Company has delivered good performance which a very few Veterinary API manufacturing Indian companies have achieved. The consistency of our performance is the outcome of a fully backward integrated process model, wherein multiple parameters and metrics work in tandem with financial and operating performance to realize sustainable growth for the long-term. The performance is underpinned by accurate know-how of molecules, catalyst chemistry, a values-driven culture, efficient capital allocation, strong corporate governance and an entrepreneurial spirit.

We are in a state of continuous evolution through a strong drive for improvement, while remaining focussed on quality, compliance, talent development, and effective risk management. Our untarnished track record and veracity in dealing with clients are key factors that inspire multiple global collaborations with reputed associates, across our businesses.

Today, the Company has emerged as:

- Amongst leading API manufacturing players to operate on completely backward integrated though catalyst chemistry

- Positioned strongly in the overall Veterinary API markets globally

- Among very few Indian companies with specialized R&D facility and a dedicated team who has a strong knowledge and experience in catalyst chemistry

The focus of the Company will continue to deliver value to our customers; to backward integrate; innovate with new molecules, which will ultimately lead to maximization of shareholder value & return.

Today India is amongst one of the fastest growing major economies in the world but growth was muted on account of various factors like policy reform setbacks, stress in Indian banking industry and lack of private sector investments amongst others. This affected growth and profitability of companies across sectors.

Seeing the trend continue, we have concentrated our efforts on bringing in efficiencies through backward integration, catalyst chemistry enhancement, product development, cost optimization and technology enhancement.

We are confident that in the coming years, along with the growth in domestic consumption & growth in economy, we will not only capture market share but also grow across India.

FUTURE PLANS

With the Government''s focus on growth of manufacturing in India and GST is in place. Globally, healthcare spending in terms of percentage to the GDP is rising. The increasing cost of bringing drugs and devices to the market and greater regulatory scrutiny are ensuing an increased demand for high-quality information and analytical support.

The global pharmaceutical market recorded yet another year of significance and the market is likely to expand many folds to us $ 1.4 trillion by 2020.

During the year, we started increasingly delivering our products and services in more efficient manner and we focus on continue doing the same in the coming years.

Going forward, we will continue to focus on our existing businesses. We also plan to launch some new molecules of API, with new product development in the coming year. We continue to build our capacities for future growth.

Human capital remains the core of our success and we have continued and will continue to invest considerable efforts in this direction not only at higher level, but till ground level. Employee engagement is the main pillar of our growth strategy. I believe that our existing talent pool will enable us to outperform our peers and meet our obligations as an organization to all our stakeholders.

I thank you all for your immense support and continued confidence in the management of our Company. I also like to thank all our stakeholders - customers, employees, partners, shareholders, business associates and society at large, for their faith in us.

Thank You.